Skip to main content
Log in

Anti-TNF switching: effect on outcomes in patients with RA

  • Practice Point
  • Published:

From Nature Clinical Practice Rheumatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Yazici Y et al. (2005) Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 64: 207–211

    Article  CAS  Google Scholar 

  2. Lindberg J et al. (2006) Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 8: R179

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

Nancy Olsen is an equity holder of Arthrochip LLC, and she provides research support to Bristol-Myers Squibb and Genentech.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olsen, N. Anti-TNF switching: effect on outcomes in patients with RA. Nat Rev Rheumatol 3, 430–431 (2007). https://doi.org/10.1038/ncprheum0535

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0535

  • Springer Nature Limited

Navigation